Revenue - Collaboration Agreement - The GSK Collaboration and License Agreement (Details) |
Jun. 30, 2023
USD ($)
|
Dec. 19, 2022
USD ($)
|
Dec. 19, 2022
GBP (£)
|
|---|---|---|---|
| Revenue | |||
| Amount of remaining deferred income under the collaboration that had not been recognized as revenue | $ 318,107,000 | ||
| GSK Collaboration And License Agreement | |||
| Revenue | |||
| Aggregate transaction price of the contract modification | $ 6,500,000 | ||
| Amount of remaining deferred income under the collaboration that had not been recognized as revenue | $ 0 | ||
| Payment by GSK due to termination of collaboration | £ | £ 5,000,000 |
| X | ||||||||||
- Definition Amount of payment due to termination of collaboration. No definition available.
|
| X | ||||||||||
- Definition Amount aggregate transaction price of the contract modification. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|